Enapotamab Vedotin or HuMax-AXL-ADC is another anti-AXL ADC, firstly tested in vitro and in vivo in preclinical models of non-small cell lung cancer [77]. The gene discussed is AXL; the disease is non-small cell lung carcinoma.